![]() Vance Thompson, Founder of Vance Thompson Vision, Sioux Falls, SD, USAīlake Williamson, Ophthalmic surgeon at the Williamson Eye Center, Baton Rouge, Louisiana, USA Raymond Radford, Independent Consultant Ophthalmic Surgeon, based in Preston, UK. Robert Osher, Professor of Ophthalmology, University of Cincinnati and Medical Director Emeritus, Cincinnati Eye Institute, Cincinnati, Ohio, USA Guy Kezirian, President of SurgiVision Consultants, Inc., Founder of the Refractive Surgery Alliance, Founder of the World College of Refractive Surgery & Visual Sciences, based in Scottsdale, Arizona, USįlorian Kretz, Founder, CEO and Lead Surgeon of Precise Vision Augenärzte, based in Rheine, Germanyīen LaHood, refractive, cataract and laser vision correction surgeon at Ashford Advanced Eye Care and The Queen Elizabeth Hospital, Adelaide, Australia Kjell Gunnar Gundersen, ophthalmic surgeon at the Ifocus Eye Clinic AS in Haugesund, Norway We invited world renowned specialists to share their perspectives.Īrthur Cummings, Consultant Ophthalmologist and Medical Director of the Wellington Eye Clinic, Dublin, Irelandĭavid Goldman, Founder and CEO of Goldman Eye, Palm Beach Gardens, Florida, USA ![]() ![]() Have US-based specialists decided to prescribe it to their patients? What have their impressions and experiences been like, and – more importantly – how have their patients reacted? What do their colleagues from other parts of the world think – are they eagerly awaiting approvals in their countries or regions and will they decide to make use of VUITY when available – or are they ambivalent? In December 2021, the manufacturer of VUITY, Allergan, an AbbVie company, announced that the eye drop was available – if prescribed – in pharmacies across the US. In late October 2021, following two Phase III clinical studies – GEMINI 1 and GEMINI 2 (1, 2) – that showed improvement in intermediate vision and no impact on distance vision of presbyopic patients for up to six hours after instillation, the FDA approved the first-ever eye drop developed to treat presbyopia: pilocarpine HCI ophthalmic solution 1.25%, better known as VUITY (3). ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |